Analysis of the forecast for healthcare expenditure on prescribed medicines in Spain reveals a consistent decrease from 2013 to 2023 in terms of GDP units, dropping from 1.11 in 2013 to 1.09 in 2023. The pattern shows an initial decline that stabilizes between 2015 and 2019 and a notable increase in 2020, likely due to the COVID-19 pandemic, which is then followed by a slight decline observed through 2023.
Year-on-year variation highlights a mixed trend with significant fluctuations such as the substantial 13.86% increase in 2020 due to unforeseen health crises, but generally minor yearly declines before and after. The last five years exhibit a small average annual growth (CAGR of 1.34% until 2023).
Looking ahead, forecast data implies a stable expenditure with no deviation predicted from 2024 to 2028 (fixed at 1.09 units of GDP), suggesting controlled and consistent investment in prescribed medicines.
Future trends to watch for include potential impacts of healthcare innovation, policy changes, demographic shifts, and geopolitical factors that may alter this forecast. Additionally, monitoring the aftermath of the COVID-19 pandemic and its effects on healthcare budgets will be crucial.
